Overview:
New treatment options for the management of refractory metastatic colorectal cancer (mCRC) offer the potential to help address critical unmet needs for patients. However, the recent progress in this space elevates critical questions about how to select a best therapeutic approach.
This virtual, rebroadcast of Show Me the Data satellite symposium, experts in the management and study of mCRC will discuss the recent evidence supporting novel therapy options in this setting, presented through the lens of challenging case scenarios highlighting potential benefits and challenges faced by patients. They will also provide insights into research that may improve outcomes for patients with mCRC in the future.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Summarize the rationale for the application of VEGFR inhibition strategies in mCRC
- Describe evidence from trials that have evaluated VEGFR inhibitors and emerging VEGFR inhibition strategies for mCRC care
- Apply recent trial results to address scenarios encountered in mCRC management and how novel approaches can be safely applied in multiple lines of mCRC care
Benefits of Attending
- Navigate the expanding treatment options for mCRC
- Get insight from the trial leaders on how to best use new options for mCRC
- Learn where we’re going next for refractory disease
CATHY ENG, MD, FACP, FASCO
Vanderbilt-Ingram Cancer Center
David H. Johnson Chair in Surgical and Medical Oncology
Professor of Medicine, Hematology and Oncology
Co-Chair, NCI Gastrointestinal Steering Committee
Co-Director, GI Oncology
Co-Leader, Gastrointestinal Cancer Research Program
Director, Young Adult Cancers Program
Nashville, TN
Sara Lonardi, MD
Head of Oncology
Dept of Oncology
Veneto Institute of Oncology IOV - IRCCS
Padua, Italy
Arvind N. Dasari, MD
Associate Professor Department of GI Medical Oncology
Division of Cancer Medicine
The University of MD Anderson Cancer Center
Houston, TX
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
